In a significant proof-of-concept test, the emerging technology of proteomics has shown its potential by distinguishing prostate cancer from benign prostate conditions, according to a report from the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). The test, which has been in development for 4 years, analyzes protein patterns in a drop of blood, and appears to be more sensitive than the prostate-specific antigen (PSA) test, at least in men with marginally elevated PSA readings, said senior NCI Scientist Lance Liotta, MD, PhD.
Vastag B. Proteomics for Prostates. JAMA. 2002;288(19):2397. doi:10.1001/jama.288.19.2397-JHA20011-3-1